Advertisement

Replication-Competent Lentivirus Analysis of Vector-Transduced T Cell Products Used in Cancer Immunotherapy Clinical Trials

  • Kenneth CornettaEmail author
  • Sue Koop
  • Emily Nance
  • Kimberley House
  • Lisa Duffy
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2086)

Abstract

Lentiviral vectors are being used in a growing number of clinical applications, including T cell immunotherapy for cancer. As this new technology moves forward, a safety concern is the inadvertent recombination and subsequent development of a replication-competent lentivirus (RCL) during the manufacture of the vector material. To assess this risk, regulators have required screening of T cell products infused into patients for RCL. Since vector particles have many of the proteins and nucleotide sequences found in RCL, a biologic assay has proven the most sensitive method for RCL detection. As regulators have required screening of up to 108 cells per T cell product, this method described a procedure for assessing RCL contamination of large-volume T cell products.

Key words

Lentiviral vectors, T cell immunotherapy, Replication-competent lentivirus, Clinical trials, CAR-T cells 

Notes

Acknowledgments

This work was supported in part by a grant from the National Heart, Lung, and Blood Institutes 9P40HL116242 to K.C.

References

  1. 1.
    Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L et al (2014) T-cell immunotherapy: looking forward. Mol Ther 22:1564–1574CrossRefGoogle Scholar
  2. 2.
    June CH, Riddell SR, Schumacher TN (2015) Adoptive cellular therapy: a race to the finish line. Sci Transl Med 7:280–287CrossRefGoogle Scholar
  3. 3.
    U.S. Food and Drug Administration (2017). FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. Accessed 4 Jan 2019
  4. 4.
    U.S. Food and Drug Administration (2018). Axicabtagene ciloleucel. https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm581222.htm. Accessed 4 Jan 2019
  5. 5.
    Schambach A, Zychlinski D, Ehrnstroem B, Baum C (2013) Biosafety features of lentiviral vectors. Hum Gene Ther 24:132–142CrossRefGoogle Scholar
  6. 6.
    Muenchau DD, Freeman SM, Cornetta K, Zwiebel JA, Anderson WF (1990) Analysis of retroviral packaging lines for generation of replication-competent virus. Virology 176:262–265CrossRefGoogle Scholar
  7. 7.
    Donahue RE, Kessler SW, Bodine D, McDonagh K, Dunbar C, Goodman D et al (1992) Helper virus induction T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 176:1125–1135CrossRefGoogle Scholar
  8. 8.
    Cornetta K, Nguyen N, Morgan RA, Muenchau DD, Hartley J, Anderson WF (1993) Infection of human cells with murine amphotropic replication-competent retroviruses. Hum Gene Ther 4:579–588CrossRefGoogle Scholar
  9. 9.
    Cornetta K, Yao J, Jasti A, Koop S, Douglas M, Hsu D et al (2011) Replication competent lentivirus analysis of clinical grade vector products. Mol Ther 19:557–566CrossRefGoogle Scholar
  10. 10.
    Sastry L, Xu J, Johnson T, Desai K, Rissing D, Marsh J et al (2003) Certification assays for HIV-1-based vectors: frequent passage of gag sequences without evidence of replication competent viruses. Mol Ther 8:830–839CrossRefGoogle Scholar
  11. 11.
    Cornetta K, Duffy L, Turtle CJ, Jensen M, Forman S, Binder-Scholl G et al (2018) Absence of replication-competent Lentivirus in the clinic: analysis of infused T cell products. Mol Ther 26(1):280–288CrossRefGoogle Scholar
  12. 12.
    U.S. Food and Drug Administration (2006) Guidance for industry - supplemental guidance on testing for replication competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors. U.S. Food and Drug Adminstration, MarylandGoogle Scholar
  13. 13.
    Escarpe P, Zayek N, Chin P, Borellini F, Zufferey R, Veres G et al (2003) Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations. Mol Ther 8:332–341CrossRefGoogle Scholar
  14. 14.
    Sastry L, Xu Y, Marsh J, Cornetta K (2005) Product enhanced reverse transcriptase (PERT) assay for detection of RCL associated with HIV-1 vectors. Hum Gene Ther 16:1227–1236CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Kenneth Cornetta
    • 1
    Email author
  • Sue Koop
    • 1
  • Emily Nance
    • 1
  • Kimberley House
    • 1
  • Lisa Duffy
    • 1
  1. 1.Department of Medical and Molecular GeneticsIndiana University School of MedicineIndianapolisUSA

Personalised recommendations